Tempest Therapeutics Stock Soars on Positive Liver Cancer Drug Trial Results

Tempest Therapeutics stock surged nearly 4,000% after positive trial results for its liver cancer drug. Market cap jumped from $3M to $130M.

Stock has moderated but remains up significantly. Current market cap around $54M.

Analysts say Tempest was undervalued before and still has "blockbuster opportunity" with cancer drug.

All analysts tracking Tempest rate it a buy. Average price target suggests 400%+ upside.

One analyst estimates Tempest could reach $770M market cap. Says current valuation is conservative based on drug's potential.